Public health authorities have described, with growing alarm, an unprecedented increase in
morbidity and mortality associated with use of opioid pain relievers (OPRs). Efforts to …

Learning Objective: After participating in this activity, learners should be better able to:
Evaluate the rationale for and current evidence supporting medication-assisted treatment of …

Most drugs of abuse easily cross the placenta and can affect fetal brain development. In
utero exposures to drugs thus can have long-lasting implications for brain structure and …

Neonatal opioid withdrawal syndrome (NOWS) has risen in prevalence from 1.2 per 1000
births in 2000 to 5.8 per 1000 births in 2012. Symptoms in neonates may include high …

Objective Buprenorphine maintenance treatment (BMT) and methadone maintenance
treatment (MMT) are pharmacological treatment programs for individuals with opioid use …

Background The prevalence of opiate use among pregnant women can range from 1% to
2% to as high as 21%. Just in the United States alone, among pregnant women with hospital …

Introduction: Management of patients with opioid use disorder (OUD) commonly includes
opioid agonist therapy (OAT) as a part of an integrated treatment plan. These interventions …

Background Pain during pregnancy is common, and its management is complex. Certain
analgesics may increase the risk for adverse fetal and pregnancy outcomes, while poorly …

CNS-active drugs are used relatively often during pregnancy. Use during early pregnancy
may increase the risk of a congenital malformation; use during the later part of pregnancy …

Aims This paper reviews the published literature regarding outcomes following maternal
treatment with buprenorphine in five areas: maternal efficacy, fetal effects, neonatal effects …